# A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Source: https://onco.cc/trials/nct03653507/  
OnCo record `nct03653507` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zolbetuximab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.

## Summary

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). is a phase 3 interventional study registered as NCT03653507 by Astellas Pharma Global Development, Inc., with 507 participants enrolled, started 2018-11-28 and due to reach its primary completion in 2022-10-25. Interventions recorded: zolbetuximab, oxaliplatin, capecitabine and placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03653507
- Phase: 3
- Setting: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 507

## Sources

- ClinicalTrials.gov NCT03653507: https://clinicaltrials.gov/study/NCT03653507

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Zolbetuximab](https://onco.cc/drugs/zolbetuximab/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct03653507.json